Individual factors and mortality associated with hormone replacement therapy in a French cohort of women from 60 to 69 years of age;Caractéristiques individuelles et mortalité associées au traitement hormonal substitutif de la ménopause: Étude d'une cohorte franaise de femmes d'âge compris entre 60 et 69 ans

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 39, Issue 6, 2010, Pages 453-465

  Ha Vinh, P ^a   Clavaud, H ^a   Sauze, L ^a  

^a Service Medical de la Caisse Regionale Provence Alpes du Regime Social des Independants   (France)

Author keywords

Health insurance organization; Menopause; Mortality rate; Postmenopausal hormone replacement therapy; Retirement insurance fund

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUTOMATION; FEMALE; FOLLOW UP; FRANCE; HEALTH INSURANCE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; POSTMENOPAUSE; QUESTIONNAIRE; REIMBURSEMENT; RETIREMENT; SELF EMPLOYMENT; STATISTICAL ANALYSIS; SURVIVAL;

AGED; COHORT STUDIES; FEMALE; FRANCE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; POSTMENOPAUSE; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 77957807209     PISSN: 03682315     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jgyn.2010.06.006     Document Type: Article

References (48)

1. H. Rochefort, and C. Sureau Les traitements hormonaux substitutifs (THS) de la ménopause : évolution récente du rapport bénéfices/risques 2004 Académie Nationale de Médecine Paris 26 p
2. Traitement hormonal substitutif de la ménopause. Caractéristiques de l'utilisation en France. Effets sur la survenue de cancers du sein et d'évnements cardiovasculaires en France Propositions d'études complémentaires. Agence franaise de sé curité sanitaire des produits de santé (Afssaps), 2005; 68 p.
3. L.A. Brinton, D. Richesson, M.F. Leitzmann, G.L. Gierach, A. Schatzkin, and T. Mouw Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort Cancer Epidemiol Biomarkers Prev 17 2008 3150 3160
4. J.V. Lacey Jr., L.A. Brinton, M.F. Leitzmann, T. Mouw, A. Hollenbeck, and A. Schatzkin Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort J Natl Cancer Inst. 98 2006 1397 1405
5. P.M. Bath, and L.J. Gray Association between hormone replacement therapy and subsequent stroke: a meta-analysis BMJ 330 2005 342 [Epub 2005 Jan 7]
6. A. Fournier, F. Berrino, E. Riboli, V. Avenel, and F. Clavel-Chapelon Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort Int J Cancer 114 2005 448 454 (Pubitemid 40279968)
7. V. Beral Million Women Study Collaborators D. Bull, J. Green, and G. Reeves Ovarian cancer and hormone replacement therapy in the Million Women Study Lancet 369 2007 1703 1710 (Pubitemid 46755369)
8. S.L. Hendrix, S. Wassertheil-Smoller, K.C. Johnson, B.V. Howard, C. Kooperberg, and J.E. Rossouw Effects of conjugated equine estrogen on stroke in the Women's Health Initiative Circulation 113 2006 2425 2434
9. R.T. Chlebowski, J. Wactawski-Wende, C. Ritenbaugh, F.A. Hubbell, J. Ascensao, and R.J. Rodabough Estrogen plus progestin and colorectal cancer in postmenopausal women N Engl J Med. 350 2004 991 1004
10. S. Hulley, D. Grady, T. Bush, C. Furberg, D. Herrington, and B. Riggs Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women JAMA 280 1998 605 613
11. J.E. Rossouw, G.L. Anderson, R.L. Prentice, A.Z. LaCroix, C. Kooperberg, and M.L. Stefanick Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
12. The Women's Health Initiative Steering Committee Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy, The Women's Health Initiative Randomized Controlled Trial JAMA 291 2004 1701 1712
13. C. Antoine, F. Liebens, B. Carly, A. Pastijn, and S. Rozenberg Influence of HRT on prognostic factors for breast cancer: a systematic review after the Women's Health Initiative Trial Hum Reprod 19 2004 741 756
14. K. Kerlikowske, D. Miglioretti, and R. Ballard-Barbash Prognostic characteristics of breast cancer among post-menopausal hormone users in a screened population J Clin Oncol 21 2003 4314 4321
15. J. Cheek, J. Lacy, S. Toth-Fejel, K. Morris, K. Calhoun, and R.F. Pommier The impact of hormone replacement therapy on the detection and stage of breast cancer Arch Surg 137 2002 1015 1019
16. K. Nanda, L.A. Bastian, and K. Schulz Hormone replacement therapy and the risk of death from breast cancer: a systematic review Am J Obstet Gynecol 186 2002 325 334
17. F. Grodstein, M.J. Stampfer, G.A. Colditz, W.C. Willett, J.E. Manson, and M. Joffe Postmenopausal hormone therapy and mortality N Engl J Med 336 1997 1769 1775
18. V. Beral Million Women Study Collaborators Breast cancer and hormone-replacement therapy in the Million Women Study Lancet 362 2003 419 427
19. S.R. Salpeter, J.M. Walsh, E. Greyber, T.M. Ormiston, and E.E. Salpeter Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis J Gen Intern Med 19 2004 791 804
20. S.R. Sturgeon, C. Schairer, L.A. Brinton, T. Pearson, and R.N. Hoover Evidence of a healthy estrogen user survivor effect Epidemiology. 6 1995 227 231
21. K. Pentti, R. Honkanen, M.T. Tuppurainen, L. Sandini, H. Kröger, and S. Saarikoski Hormone replacement therapy and mortality in 52- to 70-year-old women: the Kuopio Osteoporosis Risk Factor and Prevention Study Eur J Endocrinol 154 2006 101 107
22. B. Hedblad, J. Merlo, J. Manjer, G. Engström, G. Berglund, and L. Janzon Incidence of cardiovascular disease, cancer and death in postmenopausal women affirming use of hormone replacement therapy Scand J Public Health 30 2002 12 19
23. C. Stahlberg, E. Lynge, Z.J. Andersen, N. Keiding, B. Ottesen, and F. Rank Breast cancer incidence, case-fatality and breast cancer mortality in Danish women using hormone replacement therapy-a prospective observational study Int J Epidemiol. 34 2005 931 935 [Epub 2005 May 24]
24. M.H. Criqui, L. Suarez, E. Barrett-Connor, J. McPhillips, D.L. Wingard, and C. Garland Postmenopausal estrogen use and mortality. Results from a prospective study in a defined, homogeneous community Am J Epidemiol. 128 1988 606 614
25. T.L. Bush, L.D. Cowan, E. Barrett-Connor, M.H. Criqui, J.M. Karon, and R.B. Wallace Estrogen use and all-cause mortality. Preliminary results from the Lipid Research Clinics Program Follow-Up Study JAMA 249 1983 903 906
26. B.E. Henderson, A. Paganini-Hill, and R.K. Ross Decreased mortality in users of estrogen replacement therapy Arch Intern Med 151 1991 75 78
27. C. Rodriguez, E.E. Calle, A.V. Patel, L.M. Tatham, E.J. Jacobs, and M.J. Thun Effect of body mass on the association between estrogen replacement therapy and mortality among elderly US women Am J Epidemiol. 153 2001 145 152
28. K. Bibbins-Domingo, F. Lin, E. Vittinghoff, E. Barrett-Connor, S.B. Hulley, and D. Grady Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease Am J Cardiol. 95 2005 289 291
29. M.J. Stampfer, G.A. Colditz, W.C. Willett, J.E. Manson, B. Rosner, and F.E. Speizer Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study N Engl J Med 325 1991 756 762
30. K. Hunt, M. Vessey, and K. McPherson Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis Br J Obstet Gynaecol. 97 1990 1080 1086
31. K. Hunt, M. Vessey, K. McPherson, and M. Coleman Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy Br J Obstet Gynaecol. 94 1987 620 635
32. J.M. Sullivan, R. Vander Zwaag, J.P. Hughes, V. Maddock, F.W. Kroetz, and K.B. Ramanathan Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women Arch Intern Med. 150 1990 2557 2562
33. Ettinger B, Friedman GD, Bush T, Quesenberry CP Jr. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 1996;87(1):6-12
34. N.F. Col, M.H.[ Eckman, R.H. Karas, S.G. Pauker, R.J. Goldberg, and E.M. Ross Patient-specific decisions about hormone replacement therapy in postmenopausal women JAMA 277 1997 1140 1147
35. R.D. Gorsky, J.P. Koplan, H.B. Peterson, and S.B. Thacker Relative risks and benefits of long-term estrogen replacement therapy: a decision analysis Obstet Gynecol 83 1994 161 166
36. J.A. Cauley, D.G. Seeley, W.S. Browner, K. Ensrud, L.H. Kuller, and R.C. Lipschutz Estrogen replacement therapy and mortality among older women. The study of osteoporotic fractures Arch Intern Med. 157 1997 2181 2187
37. Trétarre B, Guizard AV, Fontaine D les membres du réseau Francim, CépiDc-Inserm. Cancer du sein chez la femme : incidence et mortalité, France 2000. INVS, BEH 44/2004 26 octobre 2004.
38. J.A. Cauley, D.G. Seeley, K. Ensrud, B. Ettinger, D. Black, and S.R. Cummings Estrogen replacement therapy and fractures in older women Ann Intern Med. 122 1995 9 16
39. Y.T. van der Schouw, and D.E. Grobbee Menopausal complaints, oestrogens, and heart disease risk: an explanation for discrepant findings on the benefits of post-menopausal hormone therapy Eur Heart J. 26 2005 1358 1361 [Epub 2005 Apr 28]
40. E. Barrett-Connor Postmenopausal estrogen and prevention bias Ann Intern Med 115 1991 455 456
41. W.F. Posthuma, R.G. Westendorp, and J.P. Vandenbroucke Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? BMJ 308 1994 1268 1269
42. J.P. Vandenbroucke How much of the cardioprotective effect of postmenopausal estrogens is real? Epidemiology 6 1995 207 208
43. K.A. Matthews, L.H. Kuller, R.R. Wing, E.N. Meilahn, and P. Plantinga Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol. 143 1996 971 978
44. D.B. Petitti Coronary heart disease and estrogen replacement therapy. Can compliance bias explain the results of observational studies? Ann Epidemiol 4 1994 115 118
45. J. Cornuz, M.A. Krieg, L. Sandini, C. Ruffieux, G. Van Melle, and P. Burckhardt Factors associated with the use of hormone replacement therapy among older women Age Ageing 32 2003 675 678
46. N.L. Keating, P.D. Cleary, A.S. Rossi, A.M. Zaslavsky, and J.Z. Ayanian Use of hormone replacement therapy by postmenopausal women in the United States Ann Intern Med 130 1999 545 553
47. J.A. Cauley, S.R. Cummings, D.M. Black, S.R. Mascioli, and D.G. Seeley Prevalence and determinants of estrogen replacement therapy in elderly women Am J Obstet Gynecol 163 1990 1438 1444
48. R.I. Horwitz, and S.M. Horwitz Adherence to treatment and health outcomes Arch Intern Med. 153 1993 1863 1868